Pretreatment HIV, immune activation levels determine their persistence during treatment

April 20, 2017
HIV infecting a human cell. Credit: NIH

A study led by a Massachusetts General Hospital (MGH) investigator may have answered a major debate in HIV research - whether the tiny amounts of HIV that persist in patients receiving long-term antiretroviral treatment (ART) cause or are caused by the elevated levels of inflammation and immune system activation that also persist during ART. In a report published in the open-access journal PLOS Pathogens, a research team from the NIH-funded AIDS Clinical Trials Group (ACTG) describes finding that pretreatment viral levels and immune activation appear to determine the extent of HIV persistence and inflammation during ART. They also found that the low levels of HIV in the blood - below what can be detected using commercial tests - did not seem to influence persistent inflammation in people on treatment.

"Our findings suggest that damage to the immune system that occurs before people are started on leads to continued immune activation, even though the medicines are keeping the virus in check," says Rajesh Gandhi, MD, of the MGH Division of Infectious Diseases, lead and corresponding author of the report. "This suggests that diagnosing HIV and starting antiretroviral therapy as soon as possible may prevent the elevated immune activation that can lead to health problems, such as heart disease. The results also suggest that new strategies focused on reducing immune activation may need to be added to novel interventions designed to reduce and eventually eliminate HIV."

Previous studies looking for possible relationships between viral levels - detected by sensitive research measures of HIV genetic material - and measures of immune activation while on ART had conflicting results, probably because they examined a single point in time without reference to patients' pretherapy status. The current investigation examined plasma and blood cell samples taken over time from 101 participants in ACTG studies - samples taken before ART, 1 and 4 years into treatment, and another taken between years 6 and 15. All participants reached and maintained viral levels undetectable by standard commercial measures by 1 year into treatment and maintained viral suppression for an average of 7 years, some for more than a decade.

Longitudinal changes in markers of inflammation after initiation of antiretroviral therapy. Credit: Gandhi RT, et al. (2017)

Measures of HIV genetic material revealed the greatest drop in viral levels occurred during the first four years on ART but also revealed a continuing but slower decline during subsequent years. While HIV levels were correlated with markers of in pretreatment samples, the association between viral levels and inflammatory markers disappeared once ART was initiated. Instead it was the pretreatment levels of both factors that appeared to determine levels of viral persistence and immune activation while on ART.

Senior author John Mellors, MD, chief of the Division of Infectious Diseases and a professor of Medicine at University of Pittsburgh School of Medicine, says, "It appears that different mechanisms are driving the stubborn persistence of HIV reservoirs and the harmful, chronic immune activation that are characteristic of HIV infection despite current treatments. This important finding is a first step towards identifying specific therapies for each problem."

Adds Gandhi, who is an associate professor of Medicine at Harvard Medical School, "Now we need to investigate viral and human genetic factors that affect HIV persistence and immune activation in people on ART and develop strategies to reduce HIV levels and inflammation that go beyond our current antiretroviral medications. Since most HIV lives in tissues, such as lymph nodes, and not in the blood, we need to look into HIV persistence and in tissues as well."

Explore further: Researchers examine the relationship between drug injection risk behaviors and immune activation

More information: PLOS Pathogens (2017). journals.plos.org/plospathogen … journal.ppat.1006285

Related Stories

Researchers examine the relationship between drug injection risk behaviors and immune activation

April 13, 2017
The use of heroin and other illicit drugs has been shown to trigger a response from the body's immune system. Consequently, high levels of immune activation (inflammation)—that is associated with the progression of chronic ...

Antiretroviral therapy may not be enough to reduce HIV-associated arterial inflammation

May 25, 2016
Initiating antiretroviral therapy (ART) soon after diagnosis of an HIV infection did not prevent the progression of significant arterial inflammation in a small group of previously untreated patients. The findings from a ...

A potential role for fat tissue as an HIV reservoir and source of chronic inflammation

September 24, 2015
Viral persistence and chronic inflammation are two key features of HIV-positive patients on antiretroviral therapy (ART). A study published on September 24th in PLOS Pathogens reports results from macaques and humans that ...

New insight into leading viral cause of congenital birth defects

April 4, 2017
A study led by Cardiff University has revealed why CMV - a virus responsible for 1000 birth defects a year in the UK - is so adept at evading the immune system. The new findings could help in the development of treatments ...

Progress toward HIV cure highlighted

February 10, 2017
A comprehensive collection of articles describing the broad scope and current status of this global effort is published in a special issue of AIDS Research and Human Retroviruses.

IL-21 repairs immune function in primate model of HIV infection

November 9, 2015
Antiretroviral drugs can suppress HIV for years, but a residual inflammatory imbalance contributes to health problems in infected individuals who are infected with the virus. A novel combination treatment aimed at repairing ...

Recommended for you

Scientists find where HIV 'hides' to evade detection by the immune system

October 19, 2017
In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memory T-cells where infectious HIV 'hides' in the human ...

National roll-out of PrEP HIV prevention drug would be cost-effective

October 18, 2017
Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) in England would be cost-effective, ...

Regulatory T cells harbor HIV/SIV virus during antiviral drug treatment

October 17, 2017
Scientists at Yerkes National Primate Research Center, Emory University have identified an additional part of the HIV reservoir, immune cells that survive and harbor the virus despite long-term treatment with antiviral drugs.

New research opens the door to 'functional cure' for HIV

October 17, 2017
In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively ...

Researchers create molecule that could 'kick and kill' HIV

October 5, 2017
Current anti-AIDS drugs are highly effective at making HIV undetectable and allowing people with the virus to live longer, healthier lives. The treatments, a class of medications called antiretroviral therapy, also greatly ...

A sixth of new HIV patients in Europe 50 or older: study

September 27, 2017
People aged 50 and older comprise a growing percentage of HIV patients in Europe, accounting for one in six new cases in 2015, researchers said Wednesday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.